SMLR Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -732.34% compared to Semler Scientific's net margin of --. Semler Scientific's return on equity of -23.56% beat Perspective Therapeutics's return on equity of --.

Semler Scientific has a consensus price target of $98.00, signalling upside risk potential of 129.46%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 241.58%. Given that Perspective Therapeutics has higher upside potential than Semler Scientific, analysts believe Perspective Therapeutics is more attractive than Semler Scientific.

Semler Scientific has a beta of 1.392, which suggesting that the stock is 39.164% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Semler Scientific quarterly revenues are $8.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Semler Scientific's net income of -$64.7M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.32x versus 29.11x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

ClearPoint Neuro has a net margin of -732.34% compared to Semler Scientific's net margin of -71.02%. Semler Scientific's return on equity of -23.56% beat ClearPoint Neuro's return on equity of -73.69%.

Semler Scientific has a consensus price target of $98.00, signalling upside risk potential of 129.46%. On the other hand ClearPoint Neuro has an analysts' consensus of $29.00 which suggests that it could grow by 154.83%. Given that ClearPoint Neuro has higher upside potential than Semler Scientific, analysts believe ClearPoint Neuro is more attractive than Semler Scientific.

Semler Scientific has a beta of 1.392, which suggesting that the stock is 39.164% more volatile than S&P 500. In comparison ClearPoint Neuro has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.296%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ClearPoint Neuro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific pays -- of its earnings as a dividend. ClearPoint Neuro pays out -- of its earnings as a dividend.

Semler Scientific quarterly revenues are $8.8M, which are larger than ClearPoint Neuro quarterly revenues of $8.5M. Semler Scientific's net income of -$64.7M is lower than ClearPoint Neuro's net income of -$6M. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while ClearPoint Neuro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.32x versus 9.74x for ClearPoint Neuro. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -732.34% compared to Semler Scientific's net margin of 6.22%. Semler Scientific's return on equity of -23.56% beat Insulet's return on equity of 36.9%.

Semler Scientific has a consensus price target of $98.00, signalling upside risk potential of 129.46%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 16.85%. Given that Semler Scientific has higher upside potential than Insulet, analysts believe Semler Scientific is more attractive than Insulet.

Semler Scientific has a beta of 1.392, which suggesting that the stock is 39.164% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Semler Scientific quarterly revenues are $8.8M, which are smaller than Insulet quarterly revenues of $569M. Semler Scientific's net income of -$64.7M is lower than Insulet's net income of $35.4M. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while Insulet's PE ratio is 51.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.32x versus 9.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -732.34% compared to Semler Scientific's net margin of 28.26%. Semler Scientific's return on equity of -23.56% beat ResMed's return on equity of 25.76%.

Semler Scientific has a consensus price target of $98.00, signalling upside risk potential of 129.46%. On the other hand ResMed has an analysts' consensus of $269.49 which suggests that it could grow by 5.99%. Given that Semler Scientific has higher upside potential than ResMed, analysts believe Semler Scientific is more attractive than ResMed.

Semler Scientific has a beta of 1.392, which suggesting that the stock is 39.164% more volatile than S&P 500. In comparison ResMed has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.603%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.83% to investors and pays a quarterly dividend of $0.53 per share. Semler Scientific pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Semler Scientific quarterly revenues are $8.8M, which are smaller than ResMed quarterly revenues of $1.3B. Semler Scientific's net income of -$64.7M is lower than ResMed's net income of $365M. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while ResMed's PE ratio is 28.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.32x versus 7.47x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.